A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
Condition: Mitochondrial Diseases
MeSH terms: Mitochondrial Diseases
Intervention: Cysteamine Bitartrate
Intervention description: Cysteamine Bitartrate Delayed-release capsules
Intervention MeSH terms: Cysteamine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Intervention model description: Open-label extension study
Masking: None (Open Label)
Enrollment: 22.0
Sex: All
Minimum age: 6 Years
Maximum age: 17 Years
Healthy volunteers: No
Keywords: Inherited mitochondrial disease; Leigh Syndrome; Leber's Hereditary Optic Neuropathy (LHON); Myoclonic epilepsy and ragged-red fibers (MERFF); Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS); Kearn-Sayre syndrome; Polymerase gamma (POLG) -related disorders; Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE)

Summary:

      A long-term extension study to assess the safety, tolerability and efficacy of cysteamine
      bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases
      who previously enrolled into study RP103-MITO-001 (NCT02023866).
    

Eligibility criteria:

        Inclusion Criteria:

          1. Completed all visits in Study RP103-MITO-001 (NCT02023866).

          2. Body weight ≥ 5 kg.

          3. The subject must be willing to abstain from initiating dietary supplements and
             non-prescribed medications except as allowed by the Investigator, throughout the study
             (from Day 1 to Study Exit).

          4. Willing and able to comply with study drug dosing requirements, i.e. ingest the RP103
             capsules intact, or sprinkled in liquid or soft food, or using a G-tube.

          5. Sexually active female subjects of childbearing potential (i.e., not surgically
             sterile [tubal ligation, hysterectomy, or bilateral oophorectomy]) must agree to
             utilize two of the following acceptable forms of contraception throughout the study
             (from Day 1 to Study Exit):

               -  Hormonal contraception: birth control pills, injection, patch, vaginal ring or
                  implant;

               -  Condom or diaphragm, with spermicide;

               -  Intrauterine device (IUD);

               -  Sterile male partner (vasectomy performed at least 6 months prior to the study).

          6. Patient's legally authorized representative must provide written informed consent;
             Patient must provide assent, if required by local/institutional requirements.

        Exclusion Criteria:

          1. Documented diagnosis of concurrent inborn errors of metabolism.

          2. Platelet count, lymphocyte count or hemoglobin below the lower limit of normal (LLN)
             at the Baseline visit.

          3. Hepatic insufficiency with liver enzyme tests (alkaline phosphatase, aspartate
             aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times the
             upper limit of normal (ULN) at the Baseline Visit.

          4. Bilirubin > 1.2 g/dL at the Baseline Visit.

          5. Inability to complete the elements of the study, e.g., coma, hemodynamic instability
             or requiring continuous ventilator support.

          6. Malabsorption requiring total parenteral nutrition (TPN), chronic diarrhea, bouts of
             pseudo obstruction.

          7. Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in
             lactic acidosis.

          8. Patients with suspected elevated intracranial pressure, pseudotumor cerebri (PTC)
             and/or papilledema.

          9. Severe gastrointestinal disease including gastroparesis.

         10. History of drug or alcohol abuse.

         11. History of pancreatitis.

         12. Participated in an investigational drug trial (except the RP103-MITO-001 study) within
             30 days or, within 90 days for a biologic, device, or surgical treatment, for
             inherited mitochondrial diseases prior to the Baseline Visit.

         13. Known or suspected hypersensitivity to cysteamine and penicillamine.

         14. Female subjects who are nursing, planning a pregnancy, known or suspected to be
             pregnant, or with a positive serum pregnancy test at the Baseline visit.

         15. Patients who, in the opinion of the Investigator, are not able or willing to comply
             with the protocol.